December 14, 2021 - Zerigo Health Expands Board of Directors

SAN DIEGO – December 14, 2021 – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the appointments of Joseph E. Giles and Christina LaMontagne to the company’s Board of Directors.…

December 9, 2021 - Zerigo Health Appoints Helen Calvin as President and Chief Commercial Officer

SAN DIEGO – December 9, 2021 – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the appointment of Helen Calvin as President and Chief Commercial Officer. She will lead Zerigo’s growing…

November 29, 2021 - On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery

WEST LAFAYETTE, INDIANA - November 29, 2021 - On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent imaging agents to target and illuminate cancer during surgery, today announced that the U.S. Food and Drug Administration (FDA) has approved CYTALUX…

November 18, 2021 - BIOVECTRA mRNA Vaccine and Bio-manufacturing Facility Announced

CHARLOTTETOWN, PRINCE EDWARD ISLAND - November 18, 2021 - BIOVECTRA today announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada. This exciting new…

November 9, 2021 - Welsh, Carson, Anderson & Stowe Acquires Majority Stake in Leiters, a 503B Outsourced Pharmaceutical Compounding Industry Leader, in Partnership with Leading Health Systems

DENVER & NEW YORK – November 9, 2021 – Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today it has acquired a majority ownership stake in Leiters, a rapidly growing leader in…

October 26, 2021 - H.I.G. BioHealth Partners Co-Leads a $52M Financing for Click Therapeutics

STAMFORD, CT – October 26, 2021 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global alternative investment firm with over $45 billion of equity capital under management,* is pleased to announce that it has co-led…

October 21, 2021 - Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

SAN DIEGO – October 21, 2021 – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced a $43 million Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna…

October 21, 2021 - BIOVECTRA Announces Appointment of Steven M. Klosk and Gordon C. McCauley to Board

CHARLOTTETOWN, PRINCE EDWARD ISLAND – October 21, 2021 – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors. “Mr.…

September 16, 2021 - Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement to Develop and Commercialize Technology to Treat Rare Conditions Associated with Coenzyme-Q10 (Ubiquinone) Deficiencies

NORTHBROOK, IL AND GREENWICH, CT - September 16, 2021 - Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and McGill University…

September 9, 2021 - Clarus Therapeutics Closes Transaction with Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies

NORTHBROOK, IL and GREENWICH, CT - September 9, 2021 - Clarus Therapeutics, Inc., a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (“Clarus”), and Blue Water Acquisition Corp.…

June 1, 2021 - Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors

SAN DIEGO – June 1, 2021 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of Georgia Erbez and Elizabeth (Liz) Cermak to its Board of Directors. Ms. Erbez and Ms. Cermak are accomplished, experienced…

May 24, 2021 - On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer

WEST LAFAYETTE, IN – May 20, 2021 - On Target Laboratories, Inc., a privately held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced results of the 006 Study, a Phase 3, randomized, multi-center, prospective, open-label…

April 27, 2021 - Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming a Publicly Listed Company to Address Unmet Needs of Men and Women Through Development of Androgen and Metabolic Therapies

Existing Clarus investors, led by H.I.G. Capital, will invest an additional $25 million in support of the company

NORTHBROOK, IL AND GREENWICH, CT – April 27, 2021 - Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and Blue Water Acquisition Corp. (NASDAQ: BLUW)…

March 30, 2021 - Augmedics, Augmented Reality Surgical Image Guidance Pioneer, Raises $36 Million in Series C Fundraising

CHICAGO – March 30, 2021 – Augmedics, a pioneer in augmented reality surgical image guidance, announced today that it has raised $36 million in an over-subscribed Series C financing with an international syndicate of Israel-US investors. This comes only eight months after the company…

March 11, 2021 - PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

MALVERN, PA & SAN DIEGO – March 11, 2021 – PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract…

January 21, 2021 - ONTOZRY™ (cenobamate) Receives Positive CHMP Opinion for the Adjunctive Treatment of Uncontrolled Focal Onset Seizures in Adults*

ZUG, SWITZERLAND – January 21, 2021 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use…

January 12, 2021 - CardioFocus Invited to Participate in 23^rd Annual ICR Conference and Needham Virtual Growth Conference

MARLBOROUGH, MA – January 12, 2021 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference,…

January 11, 2021 - CardioFocus® Annouces Expanded Distribution Partnership with Microport™ CRM to Include Spain and Portugal

MARLBOROUGH, MA – January 11, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to…

January 4, 2021 - Angelini Pharma Acquires Arvelle Therapeutics to Create a Leading European Innovator in Central Nervous System (CNS) and Mental Health Disorder Treatments

ROME – January 4, 2021 – Angelini Pharma, an international pharmaceutical company which is a part of the private ItalianAngelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovativetreatments…